Loading..

Aurinia Pharmaceuticals Inc. (AUPH) Report Analysis

Corporate Events

Positive

Aurinia Pharmaceuticals Inc. Presents Data Demo...

2022-06-03 11:05:00

Aurinia Pharmaceuticals Inc. presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephr...

Neutral

Aurinia Pharmaceuticals Inc. Presents at DGE's ...

2022-06-01 11:06:00

Aurinia Pharmaceuticals Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM. Speakers: Keely Dahl, Associa...

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thou...

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Negative

Rosen Law Firm Files Class Action Lawsuit on Be...

2022-05-24 22:15:00

Rosen Law Firm announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aurinia Pharmaceuticals Inc. betwee...

Positive

Aurinia Pharmaceuticals Inc. Presents Results f...

2022-05-20 16:07:00

Aurinia Pharmaceuticals Inc. announced for the first time the results of the AURORA 2 continuation study evaluating the long-term safety and t...

Neutral

Aurinia Pharmaceuticals Inc. Presents at EULAR ...

2022-05-17 08:50:00

Aurinia Pharmaceuticals Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022. Venue: Bella Center Copenhagen, Center Boulevar...

Neutral

Aurinia Pharmaceuticals Inc. Presents at 59th E...

2022-05-17 08:49:00

Aurinia Pharmaceuticals Inc. Presents at 59th ERA Congress 2022, May-19-2022 through May-22-2022. Presentation Date & Speakers: May-20-2022, A...

Neutral

Aurinia Pharmaceuticals Inc. Provides Earning G...

2022-05-10 10:00:00

Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 ...

Neutral

Aurinia Pharmaceuticals Inc. to Report Q1, 2022...

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022

Neutral

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings ...

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022

Negative

Pomerantz LLP Announces the Filing of Class Act...

2022-04-15 23:27:00

Pomerantz LLP announced that a class action lawsuit has been filed against Aurinia Pharmaceuticals Inc. and certain of its officers. The class...

Neutral

Aurinia Pharmaceuticals Inc., Annual General Me...

2022-04-04 13:12:00

Aurinia Pharmaceuticals Inc., Annual General Meeting, May 17, 2022, at 12:00 US Eastern Standard Time. Agenda: To elect to the board the follo...

Neutral

Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call

2022-04-04 13:12:00

Annual General Meeting

Positive

MKT Tactical Fund Discloses its Views on Aurini...

2022-03-07 00:00:00

On March 7, 2022, Aurinia Pharmaceuticals announced that MKT Tactical is campaigning for the Company to begin a strategic review. The Company ...

Positive

Aurinia Announces Positive Topline Results from...

2021-12-09 11:15:00

Aurinia Pharmaceuticals Inc. announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and toler...

Neutral

Aurinia Pharmaceuticals Inc. - Special Call

2021-12-09 11:15:00

To review these AURORA 2 topline results

Neutral

Aurinia Pharmaceuticals Inc. has filed a Shelf ...

2021-11-19 00:00:00

Aurinia Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $250 million. Security Name: Common Shares Security Name: D...

Neutral

Aurinia Pharmaceuticals Inc. Presents at 12th A...

2021-11-10 21:21:00

Aurinia Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Aurinia Pharmaceuticals Inc. Presents at ASN Ki...

2021-11-04 00:00:00

Aurinia Pharmaceuticals Inc. Presents at ASN Kidney Week 2021, Nov-04-2021 .

Neutral

Aurinia Pharmaceuticals Inc. Reaffirms Revenue ...

2021-11-03 10:00:00

Aurinia Pharmaceuticals Inc. reaffirmed revenue guidance for 2021. The company maintains its previously stated annual revenue estimate in the ...

Positive

Aurinia Pharmaceuticals Inc. Announces Updated ...

2021-11-01 14:12:00

Aurinia Pharmaceuticals Inc. announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolera...

Positive

GSK Denies Mail Report of Interest in Aurinia

2021-11-01 09:43:00

GlaxoSmithKline (GSK.L) on November 01, 2021 dismissed a Mail on October 31, 2021 report that said that the British pharma group could be inte...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings ...

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Aurinia Pharmaceuticals Inc. to Report Q3, 2021...

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

Bristol-Myers Reportedly Makes Takeover Approac...

2021-10-22 00:00:00

Bristol-Myers Squibb Company (NYSE:BMY) has expressed interest in acquiring Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH), according to people ...

Neutral

American Society of Nephrology, Inc., ASN Kidne...

2021-10-15 12:00:00

American Society of Nephrology, Inc., ASN Kidney Week 2021, Nov 04, 2021 through Nov 07, 2021.

Positive

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) add...

2021-09-20 00:00:00

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to S&P Global BMI Index

Neutral

Aurinia Pharmaceuticals Inc. Presents at Oppenh...

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 02:55 PM.

Neutral

Aurinia Pharmaceuticals Inc. Presents at Cantor...

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:40 PM. Venue: New York, United States.

Neutral

Aurinia Pharmaceuticals Inc. Presents at H.C. W...

2021-09-10 17:30:00

Aurinia Pharmaceuticals Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 03:00 PM. Venue: Lotte New York...

Positive

Aurinia Acquires Novel Pipeline Assets Targetin...

2021-08-17 10:05:00

Aurinia Pharmaceuticals Inc. announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related dise...

Positive

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired...

2021-08-17 00:00:00

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0.8 million on August 17, 2021. The acquisition ...

Neutral

Aurinia Pharmaceuticals Inc. Presents at BTIG V...

2021-08-04 12:33:00

Aurinia Pharmaceuticals Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:50 PM. Speakers: Glenn Schulman, Senior Vice Pr...

Neutral

Aurinia Pharmaceuticals Inc. to Report Q2, 2021...

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021

Neutral

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings ...

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 05, 2021

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped f...

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P Global BMI Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped f...

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Completion Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped f...

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Composite Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped f...

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Capped Composite Index

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Health...

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Negative

Aurinia Pharmaceuticals Announces Delisting fro...

2021-07-16 21:30:00

Aurinia Pharmaceuticals Inc. announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effec...

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Positive

Aurinia Pharmaceuticals Inc. Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

2022-06-03 11:05:00

Aurinia Pharmaceuticals Inc. presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in achieving the proteinuria treatment targets recommended by the European Alliance of Associations for Rheumatology (EULAR) and the European Renal Association (ERA). A post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies were presented in an oral session at the EULAR 2022 European Congress of Rheumatology by Hans-Joachim Anders, M.D., Professor of Nephrology at the University of Munich (LMU). The pooled analysis from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessed the efficacy of voclosporin, in addition to mycophenolate mofetil (MMF) and low-dose steroids, to reduce urine protein creatinine ratio (UPCR) to achieve the following EULAR/ERA treatment targets updated in 2019: =25% reduction in UPCR by three months, =50% reduction in UPCR by six months, UPCR =0.7 mg/mg by 12 months, as well as steroid dose of =7.5 mg/day at 12 months. The breakdown of the reductions in UPCR at month three, six, and 12 is as follows: At three months, 78.4% of patients in the voclosporin group and 62.4% of patients in the control group achieved =25% reduction in UPCR (OR 2.25, ??CI 1.52-3.33, p<0.0001). At six months, 66.0% of patients in the voclosporin group and 47.0% of patients in the control group achieved =50% reduction in UPCR (OR 2.24, CI 1.57-3.21, p<0.0001). At 12 months, 52.6% of patients in the voclosporin group and 33.1% of patients in the control group achieved UPCR =0.7 mg/mg (OR 2.52, CI 1.75-3.63, p<0.0001). At 12 months, 89.6% of the voclosporin group and 82.8% of the control group achieved the recommended steroid dose of =0.75 mg/day according to the protocol-defined steroid taper (OR 1.83, CI 1.03-3.27, p=0.0396). In addition, the proportion of patients meeting UPCR =0.7 and steroid dose =7.5 mg/day was 44.4% in the voclosporin group and 27.1% in the control group (OR 2.42, CI 1.66-3.53, p<0.0001).

Neutral

Aurinia Pharmaceuticals Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM

2022-06-01 11:06:00

Aurinia Pharmaceuticals Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM. Speakers: Keely Dahl, Associate Medical Director.

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Negative

Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of the Securities of Aurinia Pharmaceuticals Inc

2022-05-24 22:15:00

Rosen Law Firm announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aurinia Pharmaceuticals Inc. between May 7, 2021 and February 25, 2022, inclusive (the "Class Period"). A class action lawsuit has already been filed. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurinia was experiencing declining revenues; (2) Aurinia's 2022 sales outlook for LUPKYNIS would fall well short of expectations; (3) accordingly, Aurinia had significantly overstated LUPKYNIS's commercial prospects; (4) as a result, Aurinia had overstated its financial position and/or prospects for 2022; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Positive

Aurinia Pharmaceuticals Inc. Presents Results from the Two-Year Aurora 2 Continuation Study At the 2022 European Renal Association (Era) Congress

2022-05-20 16:07:00

Aurinia Pharmaceuticals Inc. announced for the first time the results of the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS(TM) (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus (SLE). The results were presented during an oral session at the 59th European Renal Association (ERA) Congress, held in Paris and virtually May 19-22, 2022. The AURORA 2 study assessed long-term safety and tolerability of voclosporin compared to placebo (both taken in combination with mycophenolate mofetil (MMF) and low-dose oral steroids) in patients with LN receiving treatment for an additional 24 months following completion of one year on treatment in the AURORA 1 study. The primary endpoint was safety and included assessments of adverse events, deaths, and hematological assessments. Secondary endpoints include renal response, renal flare, renal outcomes, and changes in urine protein to creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR). Voclosporin was well tolerated during the study period with a similar safety profile to control and no unexpected safety signals. Specific findings included: Ovall r rates of serious adverse events were similar in both the control (28%) and voclosporin (26.0%) armrms and there was no increase in infectious events. Generally adverse events were low and decreased over time on treatment. Significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. In AURORA 2, there was a significant difference in eGFR slope in favor of voclosporin (-0.2 mL/min/1.73 m2) compared to control arm (-5.4 mL/min/1.73 m2). There was a small, expected, and early decrease in mean eGFR in the first four weeks of treatment in AURORA 1, after which eGFR remained stable through the end of AURORA 2. The mean UPCR was lower in the voclosporin-treated groups at all time points during the three years. There were four deaths in the active control group during AURORA 2, while none in the voclosporin-treated group. A post-hoc analysis of pooled data from the AURA-LV and AURORA 1 studies was also presented during an oral session at the ERA Congress and examined the impact of voclosporin on the time to proteinuria reduction by biopsy class. The analysis reviewed pure class III, class IV, and class V biopsy groups and showed patients treated with voclosporin in addition to MMF and low dose steroids achieved earlier reductions in proteinuria across biopsy classes. These results support the efficacy results observed in the AURA-LV and AURORA 1 trials respectively, indicating a faster time to response when voclosporin is added to MMF and low-dose steroid treatment. AURORA 2 Study Design AURORA 2 (NCT03597464) is a Phase 3 randomized, double-blind, placebo-controlled clinical trial to assess the long-term safety and tolerability of voclosporin, in addition to MMF/steroids. Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with MMF at 1 g twice daily with low-dose oral steroids, for up to an additional 24 months. A total of 216 LN patients continued into AURORA 2, with 116 patients in the voclosporin-treated group and 100 patients in the active control group. About AURORA 1 The AURORA 1 study was a 52-week study designed to evaluate the efficacy and safety of LUPKYNIS (23.7 mg twice daily) when added to background therapy of MMF and corticosteroids tapered to a low dose, compared to background therapy alone in an ethnically and racially diverse patient population with active LN. Three hundred fifty-seven patients with a diagnosis of SLE and LN according to the American College of Rheumatology criteria and a kidney biopsy within two years that showed Class III, IV and/or V LN were enrolled. AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the LUPKYNIS group versus 23% in the control group (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.64-4.27; p < 0.0001). LUPKYNIS also achieved statistical significance in all pre-specified hierarchical secondary endpoints, including reduced time to 50% reduction from baseline in UPCR and time to UPCR <0.5mg/mg compared to control. The primary endpoint was complete renal response at 52 weeks defined as urine protein creatinine ratio (UPCR) <=0.5 mg/mg, with stable renal function (defined as estimated glomerular filtration rate [eGFR] >=60 mL/min/1.73 m(2) or no confirmed decrease from baseline in eGFR of >20%), no administration of rescue medication, and no more than 10 mg prednisone equivalent per day for three or more consecutive days or for seven or more days during Weeks 44 through 52. LUPKYNIS was well tolerated with no unexpected safety signals. Serious adverse events (SAEs) were reported in 21% of those treated with LUPKYNIS and in 21% of those in the control group. Results from the completed AURORA 1 study (NCT03021499) were published in May 2021 in The Lancet.

Neutral

Aurinia Pharmaceuticals Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022

2022-05-17 08:50:00

Aurinia Pharmaceuticals Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022. Venue: Bella Center Copenhagen, Center Boulevard 5, Copenhagen, Denmark. Presentation Date & Speakers: Jun-03-2022, Amit Saxena, M.D., NYU School of Medicine, Hans-Joachim Anders, Professor of Nephrology and Head of Renal Division, University of Munich.

Neutral

Aurinia Pharmaceuticals Inc. Presents at 59th ERA Congress 2022, May-19-2022 through May-22-2022

2022-05-17 08:49:00

Aurinia Pharmaceuticals Inc. Presents at 59th ERA Congress 2022, May-19-2022 through May-22-2022. Presentation Date & Speakers: May-20-2022, Anca Askanase, M.D., M.P.H., Columbia University Medical Center, Y.K. Onno Teng, President of the National Foundation of the Autoimmune Research & Collaboration Hubs.

Neutral

Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022

2022-05-10 10:00:00

Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.

Neutral

Aurinia Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022

Neutral

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022

Negative

Pomerantz LLP Announces the Filing of Class Action Against Aurinia Pharmaceuticals Inc

2022-04-15 23:27:00

Pomerantz LLP announced that a class action lawsuit has been filed against Aurinia Pharmaceuticals Inc. and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-02185, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aurinia securities between May 7, 2021 and February 25, 2022, both dates inclusive (Class Period), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: Aurinia was experiencing declining revenues; Aurinia’s 2022 sales outlook for LUPKYNIS would fall well short of expectations; accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; as a result, the Company had overstated its financial position and/or prospects for 2022; and as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 28, 2022, Aurinia issued a release announcing its financial results for the quarter and full year ended December 31, 2021. Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022.

Neutral

Aurinia Pharmaceuticals Inc., Annual General Meeting, May 17, 2022

2022-04-04 13:12:00

Aurinia Pharmaceuticals Inc., Annual General Meeting, May 17, 2022, at 12:00 US Eastern Standard Time. Agenda: To elect to the board the following nine nominees presented by the board: Dr. george m. milne, Jr., Dr. daniel billen., r. hector mackay-dunn, peter greenleaf, joseph p. hagan, Dr. david r.w. jayne, jill leversage, timothy p. walbert and Dr. brinda balakrishnan, each to serve until the 2023 annual general meeting of shareholders or until their qualified successor has been duly elected or appointed; to appoint pricewaterhousecoopers llp, chartered professional accountants, as the company's independent registered public accounting firm until the close of the 2023 annual general meeting of shareholders or until a successor is appointed; to approve, on a non-binding advisory basis, a say on pay resolution regarding the company’s executive compensation set forth in this proxy statement/circular.

Neutral

Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call

2022-04-04 13:12:00

Annual General Meeting

Positive

MKT Tactical Fund Discloses its Views on Aurinia Pharmaceuticals

2022-03-07 00:00:00

On March 7, 2022, Aurinia Pharmaceuticals announced that MKT Tactical is campaigning for the Company to begin a strategic review. The Company stated that MKT Tactical Fund has written to the Company’s chairman asking the board to hire a bank for a sale process.

Positive

Aurinia Announces Positive Topline Results from the Aurora 2 Continuation Study of Lupkynis™ (Voclosporin) for the Treatment of Adults with Active Lupus Nephritis (Ln)

2021-12-09 11:15:00

Aurinia Pharmaceuticals Inc. announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus (SLE). In combination with background immunosuppressive therapy, LUPKYNIS is the first and only FDA-approved medicine with three years of pivotal trial results, including long-term safety data, within LN. Aurinia also announced the initiation of ENLIGHT-LN, a U.S.-based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. The Company aims to initiate approximately 75 sites across the U.S. Additional details regarding this registry will be provided in 2022.

Neutral

Aurinia Pharmaceuticals Inc. - Special Call

2021-12-09 11:15:00

To review these AURORA 2 topline results

Neutral

Aurinia Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $250 million.

2021-11-19 00:00:00

Aurinia Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $250 million. Security Name: Common Shares Security Name: Debt Securities Security Name: Warrants Transaction Features: Omnibus/Universal Shelf Registration

Neutral

Aurinia Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-10 21:21:00

Aurinia Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Aurinia Pharmaceuticals Inc. Presents at ASN Kidney Week 2021, Nov-04-2021

2021-11-04 00:00:00

Aurinia Pharmaceuticals Inc. Presents at ASN Kidney Week 2021, Nov-04-2021 .

Neutral

Aurinia Pharmaceuticals Inc. Reaffirms Revenue Guidance for 2021

2021-11-03 10:00:00

Aurinia Pharmaceuticals Inc. reaffirmed revenue guidance for 2021. The company maintains its previously stated annual revenue estimate in the range of $40 to $50 million for 2021.

Positive

Aurinia Pharmaceuticals Inc. Announces Updated Interim Results from the Aurora 2 Continuation Study of Lupkynis (Voclosporin) for the Treatment of Lupus Nephritis

2021-11-01 14:12:00

Aurinia Pharmaceuticals Inc. announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. The updated results will be presented virtually on Nov. 8 during Plenary Session III at 10:45 a.m. EST during The American College of Rheumatology (ACR) Convergence 2021. In the interim analysis, patients in the voclosporin group maintained meaningful reductions in proteinuria. From pre-treatment baseline in AURORA 1 to month 30 in AURORA 2, mean urine protein/creatinine ratio (UPCR) was -3.32 mg/mg for the voclosporin group (n=90) and -2.55 mg/mg for the control group (n=78). In the voclosporin group, estimated glomerular filtration rate (eGFR), an important measurement of kidney function, remained stable through month 30. There were no unexpected new adverse events reported in the voclosporin group compared to the control group. AURORA 2 (NCT03597464) is a Phase 3 randomized, double-blind, placebo-controlled clinical trial to assess the long-term safety and tolerability of voclosporin, in addition to the standard of care, for the treatment of LN in patients with SLE. Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with mycophenolate mofetil (MMF) at 1 g twice daily with either no or low-dose oral steroids, for an additional 24 months. A total of 216 LN patients continued into AURORA 2, with 116 patients in the voclosporin group and 100 patients in the control group. 90 and 78 patients, respectively, received 30 months of total treatment as of this interim analysis. Final results from the AURORA 2 study are expected by the end of 2021. Results from the completed Phase 3 randomized, double-blind, placebo-controlled, multicenter AURORA 1 study (NCT03021499) were recently published in The Lancet.

Positive

GSK Denies Mail Report of Interest in Aurinia

2021-11-01 09:43:00

GlaxoSmithKline (GSK.L) on November 01, 2021 dismissed a Mail on October 31, 2021 report that said that the British pharma group could be interested in bidding for Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH). Britain's Mail on October 31, 2021 newspaper said, citing mounting speculation, that GSK is preparing a bid for Canada's Aurinia. The report is not true, a GSK spokesperson said in an email.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Aurinia Pharmaceuticals Inc. to Report Q3, 2021 Results on Nov 03, 2021

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

Bristol-Myers Reportedly Makes Takeover Approach to Aurinia Pharmaceuticals

2021-10-22 00:00:00

Bristol-Myers Squibb Company (NYSE:BMY) has expressed interest in acquiring Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH), according to people familiar with the matter. The company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.

Neutral

American Society of Nephrology, Inc., ASN Kidney Week 2021, Nov 04, 2021 through Nov 07, 2021

2021-10-15 12:00:00

American Society of Nephrology, Inc., ASN Kidney Week 2021, Nov 04, 2021 through Nov 07, 2021.

Positive

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to S&P Global BMI Index

2021-09-20 00:00:00

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to S&P Global BMI Index

Neutral

Aurinia Pharmaceuticals Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 02:55 PM

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 02:55 PM.

Neutral

Aurinia Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:40 PM

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:40 PM. Venue: New York, United States.

Neutral

Aurinia Pharmaceuticals Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 03:00 PM

2021-09-10 17:30:00

Aurinia Pharmaceuticals Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 03:00 PM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Positive

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-Related Diseases

2021-08-17 10:05:00

Aurinia Pharmaceuticals Inc. announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. AUR200: Recombinant Fc Protein Targeting BAFF/APRIL: The first program, AUR200, was acquired by way of Aurinia purchasing all of the common stock of Thunderbolt Pharma Inc. (Thunderbolt), a private company. AUR200 is a recombinant Fc fusion protein designed to specifically block B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand, known as APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions. For the acquisition, Aurinia made an aggregate upfront payment of $750,000 USD to the shareholders of Thunderbolt and will be responsible for future re upon investigational new drug (IND) acceptance by the United States’ Food and Drug Administration (FDA) or any equivalent authority. Additionally, Thunderbolt shareholders will receive low single digit royalties on any future net sales. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA by the end of 2022. AUR300: M2 macrophage modulation via CD206 binding: The second program, AUR300, was secured through a global licensing and research agreement with Riptide Bioscience Inc. (Riptide), a private company. AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose receptor CD206. Dysregulation of M2 macrophages drives fibrosis. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines, and therefore may have significant clinical applications for autoimmune and fibrotic diseases. Riptide has longstanding expertise in interpreting the etiology of fibrosis, including the discovery of lysyl oxidase and procollagen. As part of the agreement, Aurinia paid Riptide an upfront fee of $6 million USD. Additional milestone payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during the first half of 2023.

Positive

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0.8 million.

2021-08-17 00:00:00

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0.8 million on August 17, 2021. The acquisition also includes AUR200: Recombinant Fc Protein Targeting BAFF/APRIL. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA by the end of 2022. In a related transaction, Aurinia Pharmaceuticals secured AUR300: M2 macrophage modulation via CD206 binding through a global licensing and research agreement with Riptide Bioscience Inc. Aurinia Pharmaceuticals Inc. (TSX:AUP) completed the acquisition of Thunderbolt Pharma Inc from shareholders on August 17, 2021.

Neutral

Aurinia Pharmaceuticals Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:50 PM

2021-08-04 12:33:00

Aurinia Pharmaceuticals Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:50 PM. Speakers: Glenn Schulman, Senior Vice President of Corporate Communications & Investor Relations, Joseph M. Miller, Chief Financial Officer, Massimiliano Colao, Chief Commercial Officer, Neil Solomons, Chief Medical Officer, Peter S. Greenleaf, President, CEO & Director.

Neutral

Aurinia Pharmaceuticals Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021

Neutral

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 05, 2021

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P Global BMI Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P Global BMI Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Completion Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Completion Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Composite Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Composite Index

Negative

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Capped Composite Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Capped Composite Index

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Negative

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

2021-07-16 21:30:00

Aurinia Pharmaceuticals Inc. announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effective as of the close of trading on July 30, 2021. The Company’s common shares will no longer be traded on the TSX but will continue to trade on the Nasdaq Capital Market (Nasdaq) under the symbol AUPH. Trading on the Nasdaq accounted for approximately 94 percent of Aurinia’s daily trading volume over the past 12 months. Therefore, the Company believes that the trading volume of its shares on the TSX no longer justifies the expense and administrative efforts associated with maintaining a dual listing. The Company is confident that the transition to a single listing will help deliver better value to its shareholders, employees and of course, the patient and HCP communities it serves. Pursuant to Sec. 720(b) of the TSX Company Manual, shareholder approval is not required as an acceptable alternative market exists for the listed securities.

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Fundamental Summary

Aurinia Pharmaceuticals published its Q1 report on 2022-05-10 with positive results, but no significant factors particularly remarkable relative to its peers. Its growth and income factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Therefore, Aurinia Pharmaceuticals received an overall score of 62, translating into a HOLD ranking.

Aurinia Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 21.63 million compared to USD 0.914 million a year ago. Net loss was USD 37.63 million compared to USD 50.38 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.4 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.4 a year ago.

Business Description

Aurinia Pharmaceuticals, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Sector Overview

Aurinia Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Aurinia Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 506.9 -6.7% 67
Liabilities 58.8 -8.6% 51
Price to Book 3.4 -49.1% 47
Cash & Equivalents 132.5 -42.8% 41
Equity 448.1 -6.5% 59
EBITDA -163.7 7.4% 81
Total Revenues 66.3 45.4% 38
Parameter Value Change Score
Return on Equity -41.1 -0.7% 68
Net Cashflow -24.0 40.5% 73
Capital Expenditure -0.2 19.2% 92
Asset Turnover 0.1 58.5% 96
Free Cashflow -1.2 7.3% 79

* All values are TTM

The below chart reflects Aurinia Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Aurinia Pharmaceuticals's peer average final assessment score stands on 62.0, Aurinia Pharmaceuticals's score is 62.

  •  AUPH
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 8 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 9 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 10 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 11 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Aurinia Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Aurinia Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.

Bearish 31
Close Price 10.21
52W Low 8.94
52W High 33.08
5D MA 10.99
50D MA 11.03
200D MA 17.28
MACD -0.16
RSI 31.35
STOCH 22.69

Balance Sheet Analysis

Aurinia Pharmaceuticals's recently published balance sheet showed overall, underwhelming numbers. Both Cash & Equivalents and Book Value Factors were particularly concerning. Aurinia Pharmaceuticals did a poor job related to managing cash and cash equivalents this period, which stood at 132.5, representing a -42.8% change from the previous filing. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Consequently, their cash and cash equivalents movement received a grade of 41. Also, Aurinia Pharmaceuticals publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 3.4 and represents -49.1% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Therefore, their book value factors earned a score of 47. On the other hand, Assets, jumped out as looking rather positive. Aurinia Pharmaceuticals's management was effective in managing the value of the assets on their balance sheet, which now sits at 506.9 and represents a -6.7% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 67. Therefore, it received a cautionary score of 52.

Parameter Value Change Score
Assets 506.9 -6.7% 67
Liabilities 58.8 -8.6% 51
Price to Book 3.4 -49.1% 47
Cash & Equivalents 132.5 -42.8% 41
Equity 448.1 -6.5% 59
* All values are TTM

The below chart describes Aurinia Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Aurinia Pharmaceuticals received a balance sheet score of 52, the average of its peers stands on 65.0.

  •  AUPH
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 8 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 9 1
CareDx, Inc 1.2B 54 67 52 39 51 52 10 1
MannKind Corporation 957.2M 79 59 50 40 64 57 11 1
Merus N.V. 941.6M 59 68 50 83 81 70 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Aurinia Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Aurinia Pharmaceuticals's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -163.7, which represents a 7.4% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Therefore, its EBITDA component earned a score of 81. Also, Aurinia Pharmaceuticals's reported return on equity (ROE) ratio was -41.1, representing a change of -0.7%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 68. That said, one metric, Revenue Efficiency, stood out as particularly concerning. Aurinia Pharmaceuticals reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 66.3 and represented 45.4% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 38. Therefore, it received a score of 70.

Parameter Value Change Score
EBITDA -163.7 7.4% 81
Total Revenues 66.3 45.4% 38
Return on Equity -41.1 -0.7% 68
* All values are TTM

The below chart describes Aurinia Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Aurinia Pharmaceuticals received a income statement score of 70 , the average of its peers stands on 62.0.

  •  AUPH
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Veracyte, Inc. 1.4B 45 63 57 55 8 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 9 1
CareDx, Inc 1.2B 61 44 82 50 10 1
MannKind Corporation 957.2M 95 48 56 61 11 1
Merus N.V. 941.6M 48 60 59 54 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Asset Turnover and Capex, are driving the positive outlook for Aurinia Pharmaceuticals's financial strength. Aurinia Pharmaceuticals's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Aurinia Pharmaceuticals recorded asset turnover of 0.1, which represents a 58.5% change from the previous report. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Correspondingly, their asset turnover movement received a grade of 96. Also, Aurinia Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.2, which represents a 19.2% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. The company's CapEx movement, therefore, received a grade of 92. However, one discouraging result, Net Cash Flow, stood out. Aurinia Pharmaceuticals's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as -24.0 and represented a 40.5% change from the previous period. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Aurinia Pharmaceuticals's stock price going forward. Its net cash flow, therefore, received a grade of 73. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 84.

Parameter Value Change Score
Net Cashflow -24.0 40.5% 73
Capital Expenditure -0.2 19.2% 92
Asset Turnover 0.1 58.5% 96
Free Cashflow -1.2 7.3% 79
* All values are TTM

The below chart describes Aurinia Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Aurinia Pharmaceuticals received a cash flow score of 84, the average of its peers stands on 67.0.

  •  AUPH
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Veracyte, Inc. 1.4B 90 95 46 46 82 8 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 9 1
CareDx, Inc 1.2B 98 84 40 50 86 10 1
MannKind Corporation 957.2M 77 56 43 37 66 11 1
Merus N.V. 941.6M 70 71 74 53 71 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.